Bosentan for the treatment of pulmonary arterial hypertension ...

Bosentan Therapy for Pulmonary Arterial Hypertension

Conclusions. The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 ...

Bosentan therapy for pulmonary arterial hypertension - PubMed

The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice ...

Bosentan (Tracleer) - Pulmonary Hypertension Association

Bosentan is an oral medication approved to treat pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension.

Bosentan - StatPearls - NCBI Bookshelf

Bosentan is a medication used in the management and treatment of pulmonary artery hypertension. ... treatment of pulmonary arterial hypertension ...

Bosentan (oral route) - Mayo Clinic

Bosentan is used to treat the symptoms of pulmonary arterial hypertension (PAH) in adults or in children 3 years of age or older.

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial ...

Meta-analysis reported that targeted therapy for PAH, including endothelin receptor antagonists, phosphodiesterase five inhibitors and ...

Bosentan added to sildenafil therapy in patients with pulmonary ...

Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo ...

Treatment of patients with mildly symptomatic pulmonary arterial ...

Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension. Funding. Actelion Pharmaceuticals Ltd. Previous article ...

Treatment of Pulmonary Arterial Hypertension Using Initial ...

First-line upfront combination therapy using bosentan and iloprost in PAH subjects with WHO functional class III or IV significantly improved ...

Long-term outcome with first-line bosentan therapy in idiopathic ...

Aims Data on long-term efficacy of bosentan in unselected idiopathic pulmonary arterial hypertension (IPAH) patients are lacking. We aimed to describe the long- ...

Survival with first-line bosentan in patients with primary pulmonary ...

First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension. The treatment of primary pulmonary ...

Bosentan for the Prevention of Overcirculation-Induced ...

Background— The dual endothelin-receptor antagonist bosentan has been reported to improve pulmonary arterial hypertension, but the role of ...

Bosentan for the treatment of pulmonary arterial hypertension ...

Treatment of adults with Eisenmenger's syndrome using bosentan significantly improved functional class, saturation of oxygen at rest, and decreased levels of ...

Bosentan (Tracleer™), a New Agent for the Treatment of Pulmonary ...

in November 2001 for the treatment of PAH, to improve exercise ability and decrease the rate of clinical worsening in patients with World Health Organization ( ...

Full article: Bosentan Therapy for Pulmonary Arterial Hypertension

Bosentan is the only oral drug approved for the treatment of PAH in North America (World Health Organization [WHO] functional Class III/IV) and in Europe (WHO ...

Safety Experience With Bosentan in 146 Children 2–11 Years Old ...

The oral dual endothelin receptor antagonist bosentan has been shown to improve the short- and medium-term course of adult pulmonary arterial hypertension ...

Bosentan for the Treatment of Human Immunodeficiency Virus ...

Clinical studies have shown the importance of endothelin as a pathogenic mediator in pulmonary arterial hypertension (PAH).

Bosentan treatment in patients with primary pulmonary hypertension ...

Two controlled trials have demonstrated that bosentan improves exercise capacity in patients with PPH and pulmonary arterial hypertension (PAH) associated with ...

a subgroup analysis of the pivotal clinical trials and their open-label ...

Conclusion: Short-term bosentan treatment in a subgroup of patients with PAH secondary to CTD seems to have a favourable effect compared with placebo. The long- ...

Bosentan in the treatment of pulmonary arterial hypertension with the

Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcomes. Bosentan is an oral endothelin-1 receptor ...